Ongoing monitoring of antiretroviral products as part of WHO's Prequalification Project

Journal of Generic Medicines

Volumn 3, Issue 2, 2006, Pages 96-105

  Dekker, Theo G ^a   van Zyl, Adriaan J ^f   Gross, Olivier ^f   Taševská, Ivana ^b   Stahl, Matthias M S ^c   Rabouhans, Marie L ^d   Rägo, Lembit ^e  

^a NORTH WEST UNIVERSITY   (South Africa)

^b State Institute for Drug Control   (Czech Republic)

^c Prequalification team   (Switzerland)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF TARTU   (Estonia)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; CIPROFLOXACIN; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOEQUIVALENCE; DRUG EFFICACY; DRUG MONITORING; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; GOOD CLINICAL PRACTICE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; PATIENT COMPLIANCE; QUALITY CONTROL; SHELF LIFE; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

EID: 33751577519     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4940106     Document Type: Article

References (8)

1. Werber, Y. (2003) 'From the analyst's couch: HIV drug market', Nat. Rev. Drug Dis., Vol. 2, pp. 513-514.
2. Anon. (2002) 'Pilot procurement project for quality and sourcing (prequalification) of HIV/AIDS drugs', WHO Drug Information, Vol. l6, pp. 31-34.
3. URL: http://mednet3.who.int/prequal/
4. Good practices for national pharmaceutical control laboratories. In: WHO (2002), WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-sixth report, Annex 3 (WHO Technical Report Series, No. 902), World Health Organization, Geneva.
5. Henry, K., Brundage, R., Weller, D. et al.(2004) 'Comparison of generic Zidovudine + Lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets', Journal of Acquired Immune Deficiency Syndromes, Vol. 35, p. 537.
6. FDA Guidance for Industry (2000) 'Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system', (URL: http://www.fda.gov/cder/guidance/index.htm).
7. Lindenberg, M., Kopp, S. and Dressman, J. B. (2004) 'Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system', European Journal of Pharmaceutics and Biopharmaceutics, Vol. 58, pp. 265-278.
8. Kasim, N. A., Whitehouse, M., Ramachandran, C. et al. (2004) 'Molecular properties of WHO essential drugs and provisional biopharmaceutical classification', Molecular Pharmaceutics, Vol. 1, pp. 85-96.